Atenolol Market size was valued at USD 11.59 Billion in 2023 and is expected to reach USD 22.97 Billion by the end of 2036, expanding at around 5.4% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of atenolol is assessed at USD 12.15 Billion. The growth of the market can be attributed to the worldwide expanding ratio of hypertension among people, coupled with the surging awareness regarding the concerned complexities of hypertension. As per the World Health Organization (WHO) data, an estimated 1.28 billion persons aged 30-79 years have hypertension across the globe, with the majority two-thirds residing in low- and middle-income nations. Further, the dynamically growing demand for antihypertensive drugs throughout the world is also projected to skyrocket the growth of the global atenolol market over the forecast period.
In addition to these, factors that are believed to fuel the market growth of atenolol include the significant rise in the aged population throughout the world, as aged people are more prone to have disorders comprising hypertension, cardiac diseases, diabetes, and so on. As stated by the World Health Organization, the global population of persons aged 60 and above is projected to surge from 1 billion in 2020 to 1.4 billion by 2030. Moreover, the global population of people aged 60 and above is expected to augment to 2.1 billion by 2050. Further, poor lifestyle along with poor dietary habits among people is also estimated to fuel the market growth in the coming years.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
5.4% |
|
Base Year Market Size (2023) |
USD 11.59 Billion |
|
Forecast Year Market Size (2036) |
USD 22.97 Billion |
|
Regional Scope |
|
Application (Hypertension, Angina, Arrhythmia)
The global atenolol market is segmented and analyzed for demand and supply by application into hypertension, angina, arrhythmia, and others. Out of these four types of segments, the hypertension segment is estimated to gain the largest market share of about 55% in the year 2036. The growth of the segment can be attributed to the increasing prevalence of hypertension throughout the world, coupled with the expanding demand and consumption of antihypertensive drugs across the globe. For instance, the worldwide revenue of antihypertensive drugs is anticipated to boost by around USD 24 billion by the end of 2023. In addition to this, the rising awareness in people regarding hypertension is also estimated to fuel the segment growth in the coming years.
Distribution Channel (Hospital Pharmacies, Drug Stores, Online Pharmacies)
The global atenolol market is also segmented and analyzed for demand and supply by distribution channel into hospital pharmacies, drug stores, online pharmacies, and others. Amongst these four segments, the hospital pharmacies segment is expected to garner a significant share of around 49% in the year 2036. The growth of the segment can be attributed to the rising patient pool of hypertension, arrhythmia, angina, and so on in hospitals to get better treatment, coupled with the surging ratio of hospitals throughout the world. In addition to this, the rise in cardiovascular disorder is also anticipated to accelerate segment growth in the coming years. On the other hand, the online pharmacies segment is projected to witness an impressive CAGR during the forecast period on the back of the rising awareness of these online platforms amongst users worldwide. In addition to this, the expanding penetration of the internet throughout the world is another major factor estimated to drive segment growth across the globe in the coming years.
Our in-depth analysis of the global market includes the following segments:
|
     By Form |
|
|
    By Dosage Type |
|
|
    By Application |
|
|
   By Distribution Channel |
|
North American Market Forecast
The market share of atenolol in North America, amongst the market in all the other regions, is projected to be the largest with a share of about 40% by the end of 2036. The growth of the market can be attributed majorly to the increasing prevalence of cardiac diseases, along with the rising frequency of hypertension in the region. For instance, approximately 1 in every 18 people, or 5% of the U.S. population has arrhythmia. Furthermore, as per the statistics by the Centers for Disease Control and Prevention, in the U.S., 116 million individuals have hypertension, and in 2019, 0.5 million deaths were caused directly or indirectly by hypertension. In addition to this, the increasing availability of advanced treatment and medications, followed by the surge in healthcare expenditure is also projected to drive the growth of the atenolol market further during the projected time frame in the region.
APAC Market Statistics
The Asia Pacific atenolol market is estimated to be the second largest, registering a share of about 28% by the end of 2036. The growth of the market can be attributed majorly to the rising burden of hypertension, coupled with the surge in population, and changing lifestyle of people in the region. Besides this, the growing awareness in people regarding the use of hypertension drugs is also a significant factor anticipated to drive market growth in the region during the forecast period. In addition to this, an increase in inappropriate diet habits, coupled with the surge in fast food consumption is also estimated to drive market growth in the APAC region during the forecast period.
Europe Market Forecast
Further, the market in Europe, amongst the market in all the other regions, is projected to hold a noteworthy share of about 17% by the end of 2036. The growth of the market can be attributed majorly, as the region has witnessed a sharp hike in the cases of cardiovascular diseases. For instance, every year, more than 1.6 million deaths in the European Union and 4 million deaths in Europe are attributed to cardiovascular diseases. Moreover, efficient and inexpensive healthcare facilities in European countries are estimated to support the growth of the market. In addition to this, the surge in the life science sector is also estimated to drive the growth of the atenolol market in the European region.
Unichem Laboratories Limited obtained ANDA authorization from the United States Food and Drug Administration (USFDA) for its Atenolol and Chlorthalidone Tablets, USP 50 mg/25 mg and 100 mg/25 mg to be sold as a generic version of Alvogen Malta Operations Ltd's TENORETIC (atenolol and chlorthalidone) Tablets.
AstraZeneca PLC has approved the sale of the worldwide commercial rights Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Zestril (lisinopril), and Zestoretic (lisinopril, hydrochlorothiazide fixed-dose combination) to Atnahs Pharma. This deal has eliminated the already sold rights in the United States and India, as well as the rights in Japan, which will be kept by AstraZeneca.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?